|1.||Staskin, David R: 9 articles (09/2011 - 12/2003)|
|2.||Sand, Peter K: 6 articles (09/2011 - 03/2008)|
|3.||Oefelein, Michael G: 6 articles (09/2011 - 04/2010)|
|4.||Zinner, Norman R: 4 articles (09/2011 - 07/2005)|
|5.||Dmochowski, Roger R: 4 articles (09/2011 - 03/2008)|
|6.||Ellsworth, Pamela I: 3 articles (04/2011 - 01/2011)|
|7.||Rovner, Eric S: 3 articles (02/2011 - 01/2004)|
|8.||Madersbacher, Helmut: 3 articles (01/2010 - 07/2006)|
|9.||Zinner, Norman: 3 articles (09/2007 - 06/2004)|
|10.||Dmochowski, Roger: 3 articles (09/2007 - 02/2006)|
|1.||Overactive Urinary Bladder (Overactive Bladder)
04/01/2011 - "Once-daily extended release (XR) trospium chloride, which provides therapeutic trospium plasma concentrations over 24 hours, has demonstrated efficacy in treating overactive bladder (OAB) symptoms as evaluated over a 24-hr period. "
01/01/2011 - "This study used pooled data from 2 large, phase III, double-blind, randomized, placebo-controlled studies for a subgroup analysis of the safety and efficacy of trospium chloride extended-release (XR) in men with overactive bladder (OAB). "
02/01/2011 - "• To evaluate the safety and efficacy of once-daily trospium chloride extended release (ER) in overactive bladder syndrome (OAB) in subjects aged ≥ 75 years. "
01/01/2011 - "Safety and efficacy of once-daily trospium chloride extended-release in male patients with overactive bladder."
02/01/2013 - "Study of the population pharmacokinetic characteristics of once-daily trospium chloride 60 mg extended-release capsules in patients with overactive bladder and in healthy subjects."
06/01/2005 - "The most problematic adverse effects of trospium chloride are the anticholinergic effects of dry mouth and constipation. "
07/01/2005 - "Trospium chloride has been shown to be effective in relieving OAB symptoms, and has a favourable safety profile, showing < 1% difference for all adverse events compared with placebo, except for dry mouth, constipation and headache. "
09/01/2009 - "In addition to basic effects, trospium chloride relieved spastic constipation in patients with stroke, hypersalivation in PD and anal incontinence in MS."
01/01/2004 - "The most frequent adverse events, occurring in >1% of trospium chloride-treated patients, are dry mouth, dyspepsia, constipation, abdominal pain and nausea. "
|3.||Neurogenic Urinary Bladder (Bladder, Neurogenic)
01/01/2004 - "Placebo-controlled studies have also confirmed the efficacy of trospium chloride in terms of improved urodynamic parameters; small-scale, noncomparative studies have documented significant trospium chloride-induced improvements in patients with reflex neurogenic bladder, postoperative bladder irritation and radiation-induced cystitis; and observational studies including >10,000 patients have also revealed favourable findings for trospium chloride, including a marked decrease in incontinence episodes and substantial improvement in health-related quality of life. "
09/26/1980 - "The effect of two parasympatholytic drugs, trospium chloride and hyoscine-N-butylbromide, was studied by urodynamic tests in 20 patients with spastic neurogenic bladder function. "
09/01/2008 - "The trial of efficacy of trospium chloride (TC) in a dose of 45 mg/day in females with overactive bladder (OAB) symptoms preserved after genital prolapse (GP) surgical correction included 28 females (age 55-82, mean age 68.07 +/- 12 years). "
09/01/2008 - "[Trospium chloride in combined treatment of females with genital prolapse and overactive urinary bladder]."
|2.||quinuclidin- 3'- yl- 1- phenyl- 1,2,3,4- tetrahydroisoquinoline- 2- carboxylate monosuccinate (solifenacin)
|4.||Muscarinic Receptors (Muscarinic Acetylcholine Receptor)
|7.||Cholinergic Antagonists (Anticholinergics)
|8.||trospium chloride (Ceris)